Hormone supplementation for pubertal induction in girls

Pubertal induction in girls with ovarian insufficiency aims to mimic normal puberty, a highly complex process. Here we amalgamate the sparse global evidence and propose three options for pubertal induction regimens including oral ethinyloestradiol, and oral and transdermal 17β-oestradiol. The introd...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2017-10, Vol.102 (10), p.975-980
Main Authors: Matthews, Debbie, Bath, Louise, Högler, Wolfgang, Mason, Avril, Smyth, Arlene, Skae, Mars
Format: Article
Language:English
Subjects:
Adults
Analysis
Body Weight
Cancer therapies
Clinical outcomes
Clinical trials
Dietary supplements
Dosage and administration
Estradiol - administration & dosage
Estradiol - adverse effects
Estrogens
Ethinyl estradiol
Evidence
Female
Females
Fractions
Genetic disorders
Hormone Replacement Therapy - methods
Humans
Literature Reviews
Logical Thinking
Metabolism
Physical growth
Physiology
Primary Ovarian Insufficiency - drug therapy
Progestins - administration & dosage
Progestins - adverse effects
Puberty
Puberty - drug effects
Safety and security measures
Scientific Concepts
Treatment outcome
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pubertal induction in girls with ovarian insufficiency aims to mimic normal puberty, a highly complex process. Here we amalgamate the sparse global evidence and propose three options for pubertal induction regimens including oral ethinyloestradiol, and oral and transdermal 17β-oestradiol. The introduction of progestogens is discussed and the transition to hormone supplementation for adult women. The merits and disadvantages of the different options are detailed. The available evidence indicates that transdermal 17β-oestradiol has the most favourable efficacy, safety and cost profile but randomised controlled trials are urgently required to determine which regimen provides the best clinical outcomes.
ISSN:0003-9888
1468-2044
DOI:10.1136/archdischild-2016-311372